



Day 1 - Tuesday, October 21, 2025 Conference Room 1

<u>Time</u>	<u>Activity</u>
8:15 – 8:30	Welcome Address Julio E. Baldomero Hernández, MD, President of the Organizing Committee, Director of Clinical Research, Center for Genetic Engineering and Biotechnology (CIGB), Cuba. Francisco Hernández Bernal, MD, PhD, Scientific Secretary of Clinical Biopharm 2025.
8:30 – 9:00	Plenary Lecture 1: Marta Ayala Ávila, PhD, General Director, CIGB, Cuba. "CIGB: Forty Years of Science for Life".
9:00 – 9:30	Plenary Lecture 2: Ileana Morales Suárez, MD, PhD, Director of Science and Technological Innovation of the Ministry of Public Health, Cuba. "Health Science Governance: An innovative model for interconnection between the National Health System and industry."

Symposium No. 1: Advances in Clinical Cancer Research. Room 1

Chairpersons: Yanelys Morera Díaz, PhD, and Mayra Ramos Suzarte, PhD

Theme: Advances in Clinical Research with Biopharmaceutical Products

9:30 – 10:25	Mini-Session: Gynecological & Other Solid Tumors
9:30 – 9:50	Yanelys Morera Díaz, PhD, CIGB, Cuba. "HEBERSaVax as an active immunotherapy for ovarian cancer: phase II CENTAURO-4 trial outcomes."
9:50 – 10:05	Yudisay Reyes, MD, CIGB, Cuba. "Clinical experience with the CIGB-300 peptide: a therapeutic option for cervical cancer."
10:05 – 10:25	Mayra Ramos Suzarte, PhD, Center for Molecular Immunology (CIM), Cuba. "Itolizumab in the treatment of advanced tumors: safety and preliminary evidence of antitumor effect."



13:00 - 13:20

13:20 - 13:30

13:30



<u>Time</u>	<u>Activity</u>
10:25 – 11:20	Mini-Session: Gastrointestinal Cancers
10:25 – 10:45	Mónica Bequet Romero, PhD, CIGB, Cuba. "Rationale for active targeting of VEGF using HEBERSaVax in gastro/intestinal cancer: towards combination clinical trials."
10:45 – 11:05	Julio C. Hernández Perera, MD, PhD, Center of Medical and Surgical Research (CIMEQ), Cuba. "Safety, immunogenicity and evidence of effect of the HEBERSaVax vaccine in hepatocellular carcinoma."
11:05 – 11:20	Carmen Viada González, PhD, CIM, Cuba. "Meta-analysis of clinical trials in patients with pancreatic cancer."
11:20 – 11:30	General discussion
11:30 – 11:50	Coffee Break
Chairpers	ons: Julio R. Fernández Massó, PhD, and Julio C. Hernández Perera, PhD
11:50 – 13:20	Mini-Session: Lung Cancer Advances
11:50 – 12:10	Ramón A. Ortiz Carrodeguas, MD, Celestino Hernández University Hospital, Villa Clara, Cuba. "From clinical trials to medical practice: 25 years of experience with Cuban drugs in lung cancer in Villa Clara."
12:10 – 12:25	Carmen Viada González, PhD, CIM, Cuba. "Meta-analysis of immunotherapies for advanced lung cancer."
12:25 – 12:40	Lorena Requeiro Rodríguez, MD, CIM, Cuba. "CIMAvax-EGF from lung cancer to COPD: Redefining the treatment of chronic diseases."
12:40 – 13:00	Julio R. Fernández Massó, PhD, CIGB, Cuba. "CIGB-552 Peptide for Targeted Cancer Therapy: From Molecular Mechanism to Clinical Application."

Irina Alekseevna Leukhina, MD, P.A. Herzen Moscow Oncology Research

National Medical Research Radiological Center."

General discussion

Lunch

Institute, Russia. "mRNA technologies. Global experience. Implementation at the





Symposium No. 2: Advances in clinical research of biotechnological products for the management of chronic non-communicable / communicable diseases.

Room 2

Chairpersons: Zurina Cinza Estévez, MD, and Maria Teresa Cacua Sánchez, MD

<u>Time</u>	Activity
09:30 – 10:10	Mini-Session: Clinical research, approval, production, and market of biotechnology products
09:30 – 09:50	Christophe Clement, MSc, CEO CLEMANN Group, France. "The route for developing and reaching the market of an advanced therapy medicinal product in Europe."
09:50 – 10:10	Fabrice Heitzmann, MSc, General Manager CLEMANN Group, France . "Logistic and organizational constraints for investigational medicinal products in clinical phase in Europe."
10:10 – 11:05	Mini-Session: hrEGF for Angiology
10:10 – 10:30	Julio E. Baldomero Hernández, MD, MSc, CIGB, Cuba. "Health-Related Quality of Diabetic Foot Ulcer Patients and their Caregivers in Primary Health Care in Cuba: CAVISA study."
10:30 – 10:50	Maria Teresa Cacua Sánchez, MD, Hospital Occidente de Kennedy, Colombia. "Colombia as a pioneer and clinical benchmark in the use of hrEGF for venous and complex ulcers."
10:50 – 11:05	Antonio Panariello, General Director - Praxis Pharmaceutical Colombia. "Heberprot-P: Experiencia de la introducción en Colombia."
11:05 – 11:15	General discussion
11:15 – 11:35	Coffee Break



Melia International Varadero Oct 20-24

<u>Time</u> <u>Activity</u>

Chairpersons: Yanet A. Loret de Mola Bueno, PhD, and José Cerbino Neto, PhD

11:35 – 12:30	Mini-Session: Recombinant streptokinase, different indications
11:35 – 11:55	Francisco Hernández Bernal, MD, PhD, CIGB, Cuba. "Proctokinase®, a recombinant streptokinase suppository for the treatment of acute hemorrhoids: clinical development and real-world use."
11:55 – 12:10	Ariadna Céspedes Moncada, MD, PhD, "Dr. Juan B. Zayas Alfonso" General Hospital, Santiago de Cuba, Cuba. "Treatment with Proctokinase® suppositories vs. thrombectomy in patients with hemorrhoidal thrombosis."
12:10 – 12:30	Yanet A. Loret de Mola Bueno, MD, PhD, "Eduardo Agramonte" Pediatric Hospital, Camagüey, Cuba. "Efficacy and safety of recombinant streptokinase in parapneumonic pleural effusion in children."
12:30 – 13:30	Mini-Session: Immunobiologicals
12:30 – 12:50	José Cerbino Neto, MD, PhD, D'Or Institute for Research and Education (IDOR), Brazil. "Clinical Research in Vaccines - ICTIM development ecosystem for the clinical development of immunobiologicals."
12:50 – 13:10	Zurina Cinza Estévez, MD, MSc, PhD Student at Medical Sciences, CIGB, Cuba. "HeberNasvac®, an immunotherapeutic against chronic Hepatitis B. Post- licensing study."
13:10 – 13:30	Mónica Bequet Romero, PhD, CIGB, Cuba. "Repurposing a VEGF active immunotherapy for age related macular degeneration: CELIMAR clinical trial."
13:30 – 13:40	General discussion
13:40	Lunch





Day 2 - Wednesday, October 22, 2025 Conference Room 1

<u>Time</u>	<u>Activity</u>
09:00 – 09:30	Plenary Lecture 1: Santiago Dueñas Carrera, PhD, Vice President, BioCubaFarma. "The Clinical pathway as a pillar in the innovation setting of Cuban biopharmaceutical industry."
09:30 – 10:00	Plenary Lecture 2: Geoffrey Angus Wilson, Physicians Organizing Committee, USA. "No Matter How Great the Scientific Breakthrough, How Can U.S. Medical Doctors Access the Treatments Their Patients Need?"

Symposium No. 1: Advances in Clinical Cancer Research. Room 1

Chairpersons: Mónica Bequet Romero, PhD, and Gustavo Barroso Sánchez, MD

Theme: Innovations in Biopharmaceutical Development and Access

10:00 – 11	:00 Mini-Session: Hematological Malignancies
10:00 – 10:2	Julio D. Fernández Águila, MD, "Gustavo Aldereguía Lima" Hospital, Cienfuegos, Cuba. "Interferon alpha in the treatment of chronic myeloid leukemia. The Cuban study and its role in the era of molecularly targeted therapies."
10:20 – 10:4	Gloritza Rodríguez Matos, MD, MSc, "Camilo Cienfuegos" Provincial Hospital, Sancti Spíritus, Cuba. "Interferons in the treatment of malignant blood diseases in Sancti Spíritus. Our experience."
10:40 – 11:0	Gustavo Barroso Sánchez, MD, PhD, Institute of Hematology and Immunology, Havana, Cuba. "Unlocking myeloproliferative neoplasms: Molecular Diagnostics as the engine for Precision Therapy."
11:00 – 11:	10 General discussion
11:10 – 11:	30 Coffee Break



Melia International Varadero Oct 20-24

<u>Time</u>	<u>Activity</u>	
11:30 – 12:10	Mini-Session: Novel Antibodies & Targeted Therapies	
Ch	Chairpersons: Maria Revkova, MD, and Mónica Bequet Romero, PhD	
11:30 – 11:50	Mayra Ramos Suzarte, PhD, CIM, Cuba. "Nimotuzumab: New national and international clinical evidences in new therapeutic indications."	
11:50 – 12:10	Yanelda García Vega, MSc, CIM, Cuba. "Humanized monoclonal antibody 14F7 in solid tumors: phase I clinical trial."	
12:10 – 13:00	Mini-Session: Advances in Biotechnology, Supportive Care & Renal Cancer	
12:10 – 12:30	Olga E. Eliseo Gregorio, MD, CIGB, Cuba. "Hebervital® in the prevention or treatment of neutropenia. Post-marketing study."	
12:30 – 13:00	Maria Revkova, MD, P.A., Herzen Moscow Oncology Research Institute, Russia. "NGS-Based Cohort Stratification in Cancer Clinical Trials."	
13:00 – 13:10	General discussion	
13:10	Lunch	





Symposium No. 2: Advances in clinical research of biotechnological products for the management of chronic non-communicable / communicable diseases.

Room 2

Chairpersons: Guilherme Almeida Rosa da Silva, PhD, and Julio C. Fernández Travieso, PhD

<u>Time</u>	<u>Activity</u>
10:00 – 11:00	Mini-Session: Cardiovascular diseases
10:00 – 10:20	Julio C. Fernández Travieso, PhD, National Center for Scientific Research, Cuba. "Efficacy and safety of policosanol (20 mg/day) in cuban pre-hypertensive or grade I hypertensive patients: a randomized, double-blind, multicentre study."
10:20 – 10:40	Tania D. Carbonell Amiot, MD, PhD, "Saturnino Lora" Provincial Hospital, Santiago de Cuba, Cuba. "Cardiovascular risk prediction scale through the assessment of endothelial dysfunction."
10:40 – 11:00	Margarita Montes de Oca Carmenaty, PhD Student at Medical Sciences, "Saturnino Lora" Provincial Hospital, Santiago de Cuba, Cuba. "Predictive model of arterial stiffness in apparently healthy adults."
11:00 – 11:10	General discussion
11:10 – 11:30	Coffee Break
11:30 – 12:10	Mini-Session: Arthropathies
11:30 – 11:50	Jorge A. Gómez Morejón, MD, MSc, "10 de Octubre" Clinical-Surgical Hospital, Havana, Cuba. "Clinical evidence of Jusvinza treatment in patients with active rheumatoid arthritis. A decade of history."
11:50 – 12:10	Reynier Ramírez Suárez, DMD, PhD, "Manuel Ascunce Domenech" University Hospital, Camagüey, Cuba. "Effect and safety of ozonized platelet-rich plasma in patients with temporomandibular joint osteoarthritis."



Melia International Varadero Oct 20-24

Time	Activity

Chairpersons: Tania D. Carbonell Amiot, PhD, and Dania M. Vázquez Blomquist, PhD

12:10 – 12:50	Mini-Session: Interferon
12:10 – 12:30	Dania M. Vázquez Blomquist, PhD, CIGB, Cuba. "Safety and pharmacodynamics of intranasal recombinant human interferon alpha-2b as antiviral prophylaxis: A phase I - II clinical trial (OLIVO study)."
12:30 – 12:50	Karen Urrutia Pérez, BSc, CIGB, Cuba. "Efficacy and safety of Nasalferon in the treatment of acute upper respiratory infections in adults (ALMAS study)."
12:50 – 13:30	Mini-Session: Other research on chronic non-communicable diseases
12:50 – 13:10	Guilherme Almeida Rosa da Silva, MD, PhD, Federal University of Rio de Janeiro, Brazil. "Advances in clinical research of biotechnological products, medical devices and clinical protocol for the use of cannabidiol."
13:10 – 13:30	Arturo Chang Monteagudo, MD, MSc, Institute of Hematology and Immunology, Cuba. "Towards an Applied Pharmacogenomics in Biopharmaceuticals: Study of the Frequency of HLA in the Cuban Population."
13:30 – 13:40	General discussion
13:40	Lunch





Day 3 - Thursday, October 23, 2025 Conference Room 1

Symposium No. 1: Advances in Clinical Cancer Research. Room 1

Chairpersons: Moses Joloba, PhD, and Iraldo Bello Rivero, PhD

Theme: Future Directions and Medicine for Low-Income Countries

<u>Time</u>	<u>Activity</u>
8:30 - 9:50	Mini-Session: Skin Cancer & Local Therapies
8:30 – 8:50	Iraldo Bello Rivero, PhD, CIGB, Cuba. "HeberFERON. The impact in oncological diseases."
8:50 – 9:10	Vladimir Sánchez Linares, MD, PhD, "Juana Naranjo León" Polyclinic Center, Cuba. "Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with HeberFERON."
9:10 – 9:30	Yaniet Jiménez Montero, MD, "Carlos M. de Céspedes" Provincial Hospital, Cuba. "Effectiveness of HeberFERON versus conventional surgery in patients with basal cell carcinoma."
9:30 – 9:50	Julio C. Chi Rivas, MD, University of Medical Sciences, Santiago de Cuba, Cuba. "Treatment of basal cell carcinoma with HeberFERON® (Santiago de Cuba, 2018-2020)."
9:50 – 10:00	General discussion
10:00 – 10:20	Coffee Break





Theme: Future Directions and Medicine for Low-Income Countries

<u>Time</u>	<u>Activity</u>
10:20 – 11:40	Mini-Session: Biopharmaceutical Industry & Innovative Solutions
10:20 – 10:40	Juan Pablo Müller Galdames, MSc, Biochemical Institute of Pharmaceutical Industry LTDA, Brazil. "Brazilian Health Industrial Economic Complex, new Development Cycle: Insertion of Maricá in the National Ecosystem for the production of medicines and health products."
10:40 – 11:00	Diadelis Remírez Figueredo, PhD, CECMED, Cuba. "Regulatory Challenges in the Clinical Research. A view from Cuba."
11:00 – 11:20	Nasinguza Derrick, Uganda Cancer Institute, Uganda. "Feasibility of local production of low-cost recyclable 3D-printed Thermoplastic Masks for Radiotherapy Immobilization in Low-Income settings."
11:20 – 11:40	Duniel Abreu Casas, MD, MSc, Institute of Neurology and Neurosurgery, Cuba. "HeberFERON, a mixture of interferons for the adjuvant treatment of high-grade gliomas."
11:40 – 11:50	General discussion
11:50 – 12:30	Transition Break
12:30 – 13:15	Closing Ceremony and Awards Summary of Symposium Highlights and Presentation of Awards.





Symposium No. 2: Advances in clinical research of biotechnological products for the management of chronic non-communicable / communicable diseases.

Room 2

Chairpersons: Roberto Rodríguez Labrada, PhD, and Luis Velázquez Pérez, PhD

<u>Time</u>	<u>Activity</u>
08:30 - 08:50	Mini-Session: Public health
08:30 – 08:50	Marc Fong Shi, MD / Natalia Fajardo, members of the NVMA (Non-Violent Medicaid Army), New York, USA. "The impact of for-profit healthcare on public health and health disparities, and grassroots civil society efforts to transform the United States healthcare system."
08:50 - 11:50	Mini-Session: Neurological Disorders and Stroke
08:50 – 09:10	Luis Velázquez Pérez, MD, PhD, President of the Cuban Academy of Sciences, Cuba. "Lessons from SCA2 Studies in Cuba: Insights for Future Clinical Trial."
09:10 – 09:30	Roberto Rodríguez Labrada, PhD, Deputy Director - Cuban Neuroscience Center (CNEURO), Cuba. "Assessment of Cognitive Impairment Markers as Outcomes in Clinical Trials for Spinocerebellar Ataxias and Other Neurodegenerative Diseases."
09:30 – 09:50	Nelvys Subiros Martínez, MSc, PhD Student at Medical Sciences, CIGB, Cuba. "Neuroprotective Effects of EGF and GHRP6 in Acute Stroke: Preclinical and Clinical Evidence."
9:50 – 10:00	General discussion
10:00 – 10:20	Coffee Break
10:20 – 10:40	José L. Hernández Cáceres, PhD, CNEURO, Cuba. "Cerebellar Purkinje neurons as targets for the treatment of neurodegenerative diseases. Perspectives from biophysical modeling."
10:40 – 11:00	María A. Bobes León, PhD, CNEURO, Cuba. "ERPs reveal brain damage many years before the onset of Alzheimer disease."





<u>Time</u>	<u>Activity</u>
11:00 – 11:20	Eliseo Capote Leyva, MD, MSc, CIM, Cuba. "NeuroEPO Outcomes in Alzheimer's Disease. Clinical Strategy for Drug Registration."
11:20 – 11:35	Yaimeé Vázquez Mojena, MSc, CNEURO, Cuba. "Humoral and Cellular Markers of Chronic Peripheral Inflammation in Spinocerebellar Ataxia Type 2 (SCA2): Perspectives for Translation to Clinical Trials."
11:35 – 11:50	Rolando Zamora Fung, MD, "Hermanos Ameijeiras" Clinical-Surgical Hospital, Havana, Cuba. "Clinical characterization of the ocular motor system of subjects carrying the spinocerebellar ataxia type 2 mutation."
11:50 – 12:00	General discussion
12:00 – 12:30	Transition Break
12:30 – 13:15	Closing Ceremony and Awards Summary of Symposium Highlights and Presentation of Awards.